| 1 | = | Malignant Lung Neoplasm | 179 | 100 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 2644
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 179
ranking row 2569607 |
| 2 | = | Malignant Breast Neoplasm | 150 | 96.9 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 2627
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 150
ranking row 2569608 |
| 3 | = | Non-Hodgkin Lymphoma | 115 | 93.8 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 2168
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 115
ranking row 2569609 |
| 4 | = | Leukemia | 99 | 90.6 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 1769
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 99
ranking row 2569610 |
| 5 | = | Malignant Prostate Neoplasm | 79 | 87.5 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 1375
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 79
ranking row 2569611 |
| 6 | = | Malignant Nasopharyngeal Neoplasm | 56 | 84.4 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 261
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 56
ranking row 2569612 |
| 7 | = | Multiple Myeloma | 54 | 81.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 814
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 54
ranking row 2569613 |
| 8 | = | Malignant Gastric Neoplasm | 49 | 78.1 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 652
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 49
ranking row 2569614 |
| 9 | = | Malignant Liver Neoplasm | 46 | 75 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 906
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 46
ranking row 2569616 |
| 9 | = | Malignant Ovarian Neoplasm | 46 | 75 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 684
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 46
ranking row 2569617 |
| 9 | = | Malignant Pancreatic Neoplasm | 46 | 75 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 904
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 46
ranking row 2569615 |
| 12 | = | Malignant Esophageal Neoplasm | 41 | 65.6 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 518
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 41
ranking row 2569618 |
| 13 | = | Malignant Rectal Neoplasm | 36 | 62.5 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 386
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 36
ranking row 2569619 |
| 14 | = | Malignant Cervical Neoplasm | 34 | 59.4 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 505
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 34
ranking row 2569620 |
| 15 | = | Malignant Central Nervous System Neoplasm | 27 | 56.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 823
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 27
ranking row 2569621 |
| 16 | = | Malignant Uterine Corpus Neoplasm | 25 | 53.1 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 411
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 25
ranking row 2569622 |
| 17 | = | Malignant Bladder Neoplasm | 23 | 50 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 346
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 23
ranking row 2569623 |
| 18 | = | Malignant Colon Neoplasm | 18 | 46.9 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 225
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 18
ranking row 2569625 |
| 18 | = | Malignant Kidney Neoplasm | 18 | 46.9 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 453
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 18
ranking row 2569624 |
| 20 | = | Malignant Thyroid Gland Neoplasm | 12 | 40.6 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 176
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 12
ranking row 2569626 |
| 21 | = | Malignant Lip and Oral Cavity Neoplasm | 11 | 37.5 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 149
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 11
ranking row 2569627 |
| 22 | = | Skin Carcinoma | 8 | 34.4 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 127
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 8
ranking row 2569628 |
| 23 | = | Malignant Oropharyngeal Neoplasm | 7 | 31.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 143
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 7
ranking row 2569629 |
| 24 | = | Hodgkin Lymphoma | 6 | 28.1 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 179
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 6
ranking row 2569630 |
| 25 | = | Malignant Hypopharyngeal Neoplasm | 5 | 25 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 53
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 5
ranking row 2569632 |
| 25 | = | Malignant Laryngeal Neoplasm | 5 | 25 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 66
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 5
ranking row 2569631 |
| 27 | = | Cutaneous Melanoma | 3 | 18.8 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 78
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 3
ranking row 2569633 |
| 27 | = | Malignant Testicular Neoplasm | 3 | 18.8 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 43
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 3
ranking row 2569634 |
| 29 | = | Malignant Anal Neoplasm | 2 | 12.5 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 68
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 2
ranking row 2569636 |
| 29 | = | Malignant Vaginal Neoplasm | 2 | 12.5 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 31
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 2
ranking row 2569635 |
| 31 | = | Malignant Gallbladder Neoplasm | 1 | 6.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 32
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 1
ranking row 2569638 |
| 31 | = | Malignant Mesothelioma | 1 | 6.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 96
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 1
ranking row 2569637 |
| 31 | = | Malignant Vulvar Neoplasm | 1 | 6.3 | High confidence | clinicaltrials | inputs- asOf
- 2026-09-29
- studyType
- INTERVENTIONAL
- aggregation
- descendants
- activeTrials
- 54
- activeStatuses
- RECRUITING
- NOT_YET_RECRUITING
- ENROLLING_BY_INVITATION
- ACTIVE_NOT_RECRUITING
- formulaVersion
- ci-trial-intel-v1
- phase3Recruiting
- 1
ranking row 2569639 |